SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Bouza E.)
 

Search: WFRF:(Bouza E.) > European Society of...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00008324naa a2200553 4500
001oai:DiVA.org:oru-98292
003SwePub
008220328s2021 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-982922 URI
0247 a https://doi.org/10.1016/j.cmi.2021.09.0382 DOI
040 a (SwePub)oru
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a van Prehn, Joffreyu Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands4 aut
2451 0a European Society of Clinical Microbiology and Infectious Diseases :b 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
264 1b Elsevier,c 2021
338 a print2 rdacarrier
520 a Scope: In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for Clostridioides difficile infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as faecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on C. difficile (ESGCD) to update the 2014 treatment guidance document for CDI in adults.Methods and questions: Key questions on CDI treatment were formulated by the guideline committee and included: What is the best treatment for initial, severe, severe-complicated, refractory, recurrent and multiple recurrent CDI? What is the best treatment when no oral therapy is possible? Can prognostic factors identify patients at risk for severe and recurrent CDI and is there a place for CDI prophylaxis? Outcome measures for treatment strategy were: clinical cure, recurrence and sustained cure. For studies on surgical interventions and severe-complicated CDI the outcome was mortality. Appraisal of available literature and drafting of recommendations was performed by the guideline drafting group. The total body of evidence for the recommendations on CDI treatment consists of the literature described in the previous guidelines, supplemented with a systematic literature search on randomized clinical trials and observational studies from 2012 and onwards. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The guideline committee was invited to comment on the recommendations. The guideline draft was sent to external experts and a patients' representative for review. Full ESCMID endorsement was obtained after a public consultation procedure.Recommendations: Important changes compared with previous guideline include but are not limited to: metronidazole is no longer recommended for treatment of CDI when fidaxomicin or vancomycin are available, fidaxomicin is the preferred agent for treatment of initial CDI and the first recurrence of CDI when available and feasible, FMT or bezlotoxumab in addition to standard of care antibiotics (SoC) are preferred for treatment of a second or further recurrence of CDI, bezlotoxumab in addition to SoC is recommended for the first recurrence of CDI when fidaxomicinwas used to manage the initial CDI episode, and bezlotoxumab is considered as an ancillary treatment to vancomycin for a CDI episode with high risk of recurrence when fidaxomicin is not available. Contrary to the previous guideline, in the current guideline emphasis is placed on risk for recurrence as a factor that determines treatment strategy for the individual patient, rather than the disease severity.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Infektionsmedicin0 (SwePub)302092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Infectious Medicine0 (SwePub)302092 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Mikrobiologi inom det medicinska området0 (SwePub)301092 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Microbiology in the medical area0 (SwePub)301092 hsv//eng
7001 a Reigadas, Elenau Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain4 aut
7001 a Vogelzang, Erik H.u Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands4 aut
7001 a Bouza, Emiliou Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain4 aut
7001 a Hristea, Adrianau University of Medicine and Pharmacy Carol Davila, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania4 aut
7001 a Guery, Benoitu Infectious Diseases Specialist, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland4 aut
7001 a Krutova, Marcelau Department of Medical Microbiology, Charles University in Prague and Motol University Hospital, Czech Republic4 aut
7001 a Norén, Torbjörn,d 1955-u Örebro universitet,Institutionen för medicinska vetenskaper,Department of Laboratory Medicine, National Reference Laboratory for Clostridioides difficile, Clinical Microbiology, Örebro University Hospital, Örebro, Sweden4 aut0 (Swepub:oru)trnn
7001 a Allerberger, Franzu Austrian Agency for Health and Food Safety (AGES), Vienna, Austria4 aut
7001 a Coia, John E.u Department of Clinical Microbiology, Hospital South West Jutland and Department of Regional Health Research IRS, University of Southern Denmark, Esbjerg, Denmark4 aut
7001 a Goorhuis, Abrahamu Department of Infectious Diseases, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, the Netherlands4 aut
7001 a van Rossen, Tessel M.u Department of Medical Microbiology and Infection Control, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands4 aut
7001 a Ooijevaar, Rogier E.u Department of Gastroenterology, Amsterdam University Medical Center, Location VUmc, Amsterdam, the Netherlands4 aut
7001 a Burns, Karenu Departments of Clinical Microbiology, Beaumont Hospital & Royal College of Surgeons in Ireland, Dublin, Ireland4 aut
7001 a Olesen, Bente R. Scharviku Department of Medical Microbiology, Herlev, Denmark4 aut
7001 a Tschudin-Sutter, Sarahu Department of Infectious Diseases and Infection Control, University Hospital Basel, University Basel, Universitatsspital, Basel, Switzerland4 aut
7001 a Wilcox, Mark H.u Department of Microbiology, Old Medical, School Leeds General Infirmary, Leeds Teaching Hospitals & University of Leeds, Leeds, United Kingdom4 aut
7001 a Vehreschild, Maria J. G. T.u German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany4 aut
7001 a Fitzpatrick, Fidelmau Department of Clinical Microbiology, Beaumont Hospital, Dublin, Ireland; Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland4 aut
7001 a Kuijper, Ed J.u Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlands; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands4 aut
7102 a Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, the Netherlandsb Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain4 org
7730 t Clinical Microbiology and Infectiond : Elsevierg 27:Suppl. 2, s. S1-S21q 27:Suppl. 2<S1-S21x 1198-743Xx 1469-0691
8564 u https://doi.org/10.1016/j.cmi.2021.09.038y Fulltext
8564 u http://www.clinicalmicrobiologyandinfection.com/article/S1198743X21005681/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-98292
8564 8u https://doi.org/10.1016/j.cmi.2021.09.038

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view